Physician profile
Ryan Alan Shields
NPI 1255726618
$10,202.15
in general payments reported to CMS, 2019-2025
31 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,119 · 2020: $155 · 2021: $443 · 2022: $1,712 · 2023: $1,836 · 2024: $3,143 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,658 · Consulting Fee: $2,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,658.11 |
| Consulting Fee | $2,115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,267.35 | 2019-2025 | Vabysmo, Susvimo |
| Alcon Vision LLC | $1,552.34 | 2019-2025 | Unity, Constellation |
| Regeneron Healthcare Solutions, INC. | $1,406.28 | 2019-2025 | Eylea, Eylea Hd |
| Coherus Oncology, INC. | $467.81 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $408.67 | 2019-2020 | |
| Harrow Eye, LLC | $338.63 | 2024-2025 | Iheezo |
| Johnson & Johnson Surgical Vision, INC. | $247.49 | 2021-2023 | Tecnis Iol |
| Horizon Therapeutics Plc | $238.66 | 2022 | |
| Mallinckrodt Hospital Products INC. | $205.77 | 2022-2024 | Acthar |
| Dutch Ophthalmic, USA | $153.04 | 2023-2024 | Tissueblue, Eva, Combined Machine |
| Alimera Sciences, INC. | $146.49 | 2019-2024 | Yutiq, Iluvien |
| Carl Zeiss Meditec USA, INC. | $139.32 | 2025 | |
| Apellis Pharmaceuticals, INC. | $134.61 | 2023-2025 | Syfovre |
| New World Medical,INC. | $127.42 | 2024 | Kahook Dual Blade, Streamline, Clearpath |
| Rayner Intraocular Lenses Limited | $124.99 | 2023 | Omidria |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $122.83 | 2022-2023 | Eylea |
| Ocular Therapeutix, INC. | $120.71 | 2023 | Dextenza |
| Biotissue Holdings INC. | $120.07 | 2022 | |
| Ani Pharmaceuticals, INC. | $112.20 | 2024-2025 | Yutiq, Purified Cortrophin Gel, Iluvien |
| Omeros Corporation | $109.27 | 2021 | |
| Eyevance Pharmaceuticals LLC | $109.10 | 2022 | |
| Carl Zeiss Meditec Cataract Technology INC. | $91.00 | 2022 | |
| Allergan, INC. | $85.16 | 2019-2020 | |
| Stryker Corporation | $81.44 | 2019 | |
| Eyepoint US, INC. | $69.79 | 2019-2021 | |
| Astellas Pharma US INC | $59.55 | 2024-2025 | Izervay |
| Viiv Healthcare Company | $59.02 | 2023 | Cabenuva |
| Sandoz INC. | $33.27 | 2024 | Cimerli |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.81 | 2019-2020 | |
| Abbvie INC. | $21.13 | 2025 | |
| Neurotech Pharmaceuticals, INC. | $19.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.